Chloe Jayne Bright

Chloe Jayne Bright

Auto-generated profile, based on publicly available information

Chloe Jayne Bright

National Cancer Registration and Analysis Service Public Health England London UK

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2022 in European Journal of Cancer Care
Verified
Journal Article
Open access
Judith EberhardtJudith Eberhardt
Judith Eberhardt
CBChloe J. Bright
Chloe J. Bright
CGCarolyn Gildea
Carolyn Gildea
OAOsa Adeghe
Osa Adeghe
VMVivian Mak
Vivian Mak
LELucy Elliss‐Brookes
Lucy Elliss‐Brookes
More than a third of women diagnosed with breast cancer in England, and over half of those who die from it, are over 70. The Be Clear on Cancer Breast Cancer in Women over 70 Campaign, running three times, 2014–2018, aimed to promote early diagnosis of breast cancer in England by raising symptom awareness and encouraging women to see their general practitioner (GP) without delay. We sought to establish whether the third campaign had successfully met its aims. Metrics covering the patient pathway, including symptom awareness, attending a GP practice with symptoms, urgent GP referral, diagnosis and stage of cancer, were assessed using national cancer databases and two household surveys. The third campaign was associated with an increase in urgent cancer referrals, and therefore mammograms and ultrasounds performed. This was associated with an increase in breast cancers diagnosed. There was a delayed effect on GP attendances. Awareness of breast cancer prevalence for the 70‐and‐over age group improved. Impact on these metrics diminished across successive campaigns. Future campaigns should focus on harder‐to‐reach women and include GPs as targets as this campaign showed a potential to affect referral behaviour.

15 May 2022 in European Journal of Cancer Care
Verified
Journal Article
Open access
SMSamuel Merriel
Samuel Merriel
SBSusan Ball
Susan Ball
CBChloe Jayne Bright
Chloe Jayne Bright
VMVivian Mak
Vivian Mak
CGCarolynn Gildea
Carolynn Gildea
LELucy Elliss‐Brookes
Lucy Elliss‐Brookes
To assess the impact of the fourth Be Clear on Cancer (BCoC) ‘Blood in Pee’ (BiP) campaign (July to September 2018) on bladder and kidney cancer symptom awareness and outcomes in England. In this uncontrolled before and after study, symptom awareness and reported barriers to GP attendance were assessed using panel and one‐to‐one interviews. The Health Improvement Network (THIN), National Cancer Registration and Analysis Service (NCRAS) and NHS Cancer Waiting Times (CWT) data were analysed to assess the impact on GP attendances, urgent cancer referrals, cancer diagnoses and 1‐year survival. Analyses used Poisson, negative binomial and Cox regression. Symptom awareness and intention to consult a GP after one episode of haematuria increased following the campaign. GP attendance with haematuria (rate ratio (RR) 1.17, 95% confidence interval (CI): 1.07–1.28) and urgent cancer referrals (RR 1.18 95% CI: 1.08–1.28) increased following the campaign. Early‐stage diagnoses increased for bladder cancer (difference in percentage 2.8%, 95% CI: −0.2%–5.8%), but not for kidney cancer (difference −0.6%, 95% CI: −3.2%–2.1%). The fourth BCoC BiP campaign appears to have been effective in increasing bladder cancer symptom awareness and GP attendances, although long‐term impacts are unclear.

11 August 2021 in European Journal of Cancer Care
Verified
Journal Article
Open access
PDF file
NTNicola Torrance
Nicola Torrance
CBChloe J. Bright
Chloe J. Bright
HHHelen L. Hill
Helen L. Hill
JFJennie Fergusson
Jennie Fergusson
CKCatriona Kennedy
Catriona Kennedy
LELucy Elliss‐Brookes
Lucy Elliss‐Brookes
Objective A regional ‘Be Clear on Cancer’ (BCoC) campaign developed by Public Health England aimed to promote public awareness of key abdominal cancer symptoms in people aged 50 years and over. Methods Data were analysed for metrics at different stages in the patient care pathway including public awareness, GP attendance and referrals, to cancer diagnosis. Results There was significantly higher recognition of the BCoC abdominal campaign in the campaign region compared to the control area (Post Campaign/Control, n = 401/406; 35% vs. 24%, p < 0.05). The campaign significantly improved knowledge of ‘bloating’ as a symptom (p = 0.03) compared to pre-campaign levels. GP attendances for abdominal symptoms increased significantly by 5.8% (p = 0. 03), although the actual increase per practice was small (average 16.8 visits per week in 2016 to 17.7 in 2017). Urgent GP referrals for suspected abdominal cancer increased by 7.6%, compared to a non-significant change (0.05%) in the control area. For specific abdominal cancers, the number diagnosed were similar to or higher than the median in the campaign area but not in the control area in people aged 50 and over: colorectal (additional n = 61 cancers), pancreatic (additional n = 102) and stomach cancers (additional n = 17). Conclusions This campaign had a modest impact on public awareness of abdominal cancer symptoms, GP attendances and cancers diagnosed.

3 September 2025 in British Journal of Dermatology
Verified
Journal Article
Open access
KMKhaylen Mistry
Khaylen Mistry
PJPolly Jeffrey
Polly Jeffrey
NLNick J Levell
Nick J Levell
OKOliver Kennedy
Oliver Kennedy
KRKathryn Richardson
Kathryn Richardson
ZVZoe C Venables
Zoe C Venables
Background: Inadequacy of testing for melanoma BRAF status results in delayed access to systemic therapy. BRAF mutations and their association with patient/tumour characteristics and survival is poorly understood. Objectives: To report national data from England on the frequency of molecular BRAF testing; the association of patient/tumour characteristics with BRAF mutations; and the treatment and survival of patients with BRAF mutations. Methods: This national retrospective cohort study identified all new melanomas and molecular BRAF testing in England diagnosed from 2016 to 2021 using population-based data from the National Disease Registration Service. Multivariate logistic regression determined the association between BRAF testing with patient/tumour characteristics and BRAF genotype with patient/tumour characteristics. Age-standardized net survival analysed melanoma-specific mortality by BRAF genotype. Results: Of new cases of melanoma, 14% (n = 13 138/91 415) had a BRAF test registered. The proportion of successfully tested tumours that were BRAF-mutated was 34% (n = 4424/13 012). The West Midlands tested the highest proportion of cutaneous tumours (23%; n = 1783/7901) vs. the lowest in Yorkshire and the Humber (11%; n = 856/7760). Female patients [odds ratio (OR) 0.82, 95% confidence interval (CI) 0.79–0.86] and those aged > 80 years (OR 0.88, 95% CI 0.83–0.93) were less likely to be tested for BRAF mutations. BRAF mutations were associated with female gender (OR 1.16, 95% CI 1.07–1.26). Patients aged > 80 (OR 0.36, 95% CI 0.32–0.40) had lower odds of having BRAF-mutated tumours. Patients with BRAF mutations had a lower 5-year net survival [55.9% (95% CI 52.7–59.2) vs. BRAF wildtype 5-year net survival 62.2% (95% CI 60.1-64.5)], particularly in stage II disease. Conclusions: This study presents the largest dataset on national melanoma BRAF status published to date. The data highlight geographical and demographic variations in BRAF testing and the impact of BRAF mutations on survival rates, particularly in patients with stage II disease. This highlights the critical role of consistent, early and accurate testing to ensure equal care, guide treatment decisions and understand prognosis.

27 May 2022 in European Journal of Cancer Care
Verified
Journal Article
Closed access
CBChloe J. Bright
Chloe J. Bright
CDCasey Dunlop
Casey Dunlop
CCCong Chen
Cong Chen
RSRebecca Smittenaar
Rebecca Smittenaar
SMSean McPhail
Sean McPhail
EKEmma Kipps
Emma Kipps
Objective Patients with incurable breast cancer may be treated with chemotherapy to improve cancer-related symptoms, quality of life and survival. We examined the association between use of palliative chemotherapy towards the end of life in breast cancer patients and outcomes including unplanned hospital admission and place of death. Methods A total of 10,966 women, treated with palliative chemotherapy for breast cancer (diagnosed 1995-2017 in England) within the 2 years prior to death (death between 2014 and 2017), were analysed. Logistic regression (outcome = emergency hospital admission in last 90 days of life yes/no; outcome = place of death hospital/other) was performed, adjusting for line of palliative chemotherapy in the last 90 days of life and patient demographics. Results The odds of hospital admission reduced with increasing line of chemotherapy received (1st line odds ratio [OR] = 2.7, 2nd line OR = 2.1, 3rd line OR = 1.9, 4th+ line OR = 1.7; baseline chemotherapy) in last 90 days of life. A similar relationship was observed for hospital death (1st line OR = 2.4, 2nd line OR = 2.1, 3rd line OR = 1.7, 4th+ line OR = 1.5). Conclusion This study finds palliative chemotherapy towards the end of life to be associated with increased odds of unplanned hospital admissions and hospital death. These findings can be used to inform discussions between patients and healthcare professionals towards the end of life.

26 August 2022 in Journal of Epidemiology and Community Health
Verified
Conference Paper
Closed access
PDF file
RHRoger Hill
Roger Hill
JBJohn Broggio
John Broggio
KFKate Fleming
Kate Fleming
CBChloe Bright
Chloe Bright
Background Childhood cancer survival figures have improved between 2002 and 2019. However, these overall figures may mask differences in survival for children living in different socioeconomic conditions as seen in adult cancer survival. Methods We estimated 5- and 10-year survival figures for children diagnosed with cancer between 2002 and 2019 using data from the National Cancer Registration and Analysis Service. Where full follow-up information was available survival was estimated using the cohort approach; where full follow-up was not available estimates of survival used the period approach, which assumes that people will experience the most recently observed conditional probabilities of survival in each year up to 5 or 10 years since diagnosis. Survival estimates were stratified based on an area based measure of deprivation in which postcode of residence was mapped to quintiles of the Index of Multiple Deprivation (IMD). All estimates are age-standardised using equal weights for each of the 5-year age groups (0–4, 5–9 and 10–14years). Locally weighted regression smoothing was applied to highlight trends over time. Results Consistently lower 5- and 10- year survival estimates were seen for children diagnosed with cancer living in the most deprived quintile compared with those living in the least deprived quintile. 5-year survival was between 0.4 and 5.8 percentage points lower, and 10-year survival between 0.1 and 7.9 percentage points lower, in children living in the most deprived quintile compared with those living in the least deprived quintile. The most pronounced differences in trends in survival estimates were seen for 10-year survival which showed a sharp divergence for children diagnosed with cancer between 2008–2011 dependent on their deprivation quintile. Children living in the least deprived quintile showed an increase in 10-year survival from 75.5% in children diagnosed in 2002 to 82.9% in those diagnosed in 2010, and a marginal increase to 83.8% in those diagnosed in 2019. In contrast, children living in the most deprived quintile showed an increase in survival from 72.7% to 79.1% for those diagnosed in 2002 to those diagnosed in 2007, followed by a decrease to a low of 75.3% for those diagnosed in 2011, with survival estimates only reaching 2007 levels again for those diagnosed in 2019 (79.3%). Conclusion Stark inequalities in both 5- and 10-year survival appeared for children diagnosed around 2008–2011 with children living in the most deprived quintiles having lower survival estimates than those living in the least deprived quintiles. Inequalities in survival estimates were seen throughout the 2010s.